Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Eli Lilly already has market share in the breast cancer space with the approved drug Verzenio (abemaciclib), and is advancing ...

Eli Lilly’s Verzenio is already one of its fastest-growing products, but could go up another gear following a pair of FDA approvals that expand its eligible patient population – particularly ...

Eli Lilly has turned to a biotechnology startup for help building ... to study STX-678 together with a so-called CDK4 ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

The general mood among these heavyweight investors is divided, with 36% leaning bullish and 42% bearish. Among these notable ...

The Indianapolis-based drugmaker will acquire Scorpion’s STX-478, a once-daily oral treatment in early trials for breast cancer and other advanced solid tumors.

Eli Lilly and Company discovers ... Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE ... In the third quarter, Lilly's revenue from the breast cancer drug Verzenio increased by 32% year over year to $1.4 billion. Sales from the ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity ...